
|Articles|May 20, 2020
ASCRS 2020: Intraocular dexamethasone, moxifloxacin vs topical regimen
Author(s)Alex Delaney-Gesing
Advertisement
Ophthalmology Times' David Hutton speaks with John A. Hovanesian, MD, about the highlights of his presentation on patient-reported tolerance and satisfaction with intraocular administration of dexamethasone and moxifloxacin versus a topical regimen, during the 2020 ASCRS virtual meeting.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025 Takeaways: A new biomechanical paradigm for presbyopia
2
AAO 2025 Takeaways: Cornea, refractive surgery, and aesthetics redefined
3
AAO 2025 Takeaways: The new era of glaucoma treatment and surgical precision
4
Clinical Experience and Integration of New Dry Eye Disease Therapies in the Clinic
5

















































.png)


